Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically-confirmed disease~   * Phase 1: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinomas who are considered to have platinum-resistant disease (progression within 6 months from completion of platinum-based chemotherapy).~  * Phase 2: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinomas who are considered to have platinum-resistant disease (progression within 6 months from completion of a minimum of 4 platinum therapy cycles).~2. Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1~3. Agree to provide core biopsies at baseline and at Cycle 2 Day 15~4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~5. Available archived tumor tissue for central analysis~6. Adequate organ and marrow function~Exclusion Criteria~1. Platinum-refractory disease (progression during the first platinum-based chemotherapy)~2. Major surgical procedure within 4 weeks prior to Study Day 1~3. Inaccessible tumors or for whom biopsy is contraindicated~4. Clinically significant ascites~5. Phase 2 only: Previous treatment with \>3 chemotherapy regimens for locally advanced or metastatic disease~6. Active bowel obstruction, or hospitalization for bowel obstruction within 2 months prior to screening~7. Require parenteral nutrition~8. Hospitalization within 2 weeks prior to screening~9. Received any anticancer medication or therapy in the 21 days prior to study Day 1~10. Prior monoclonal antibody treatment within 4 weeks before study Day 1~11. History of listeriosis or previous treatment with a listeria-based immunotherapy~12. Known allergy to both penicillin and sulfa antibiotics~13. Any immunodeficiency disease or immune-compromised state~14. Received prior immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, anti PDL-1) and any other antibody or drug specifically targeting T-cell costimulation or an IDO inhibitor~15. Pregnant or breastfeeding~16. Clinically significant heart disease~17. Valvular heart disease that requires antibiotic prophylaxis for prevention of endocarditis~18. History of any autoimmune disease which required systemic therapy in the past 2 years~19. Diagnosed with another malignancy within the past 3 years~20. Currently receiving therapy with a UDP-glucuronosyltransferase 1A9 inhibitor including diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid~21. Receiving monoamine oxidase inhibitor (MAOIs) or a drug which has significant MAOI activity (meperidine, linezolid, methylene blue) within the 21 days before screening~22. Had prior serotonin syndrome~23. Has implanted medical devices that pose high risks for colonization and cannot be easily removed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: CRS-207 (Type: EXPERIMENTAL): CRS-207 administered in 3-week cycles.~\* CRS-207 (1 x 10e9 colony forming units \[CFU\]) administered by intravenous (IV) infusion. For Cycle 1 through Cycle 6, CRS-207 will be administered on Day 1 of each cycle. After 6 cycles, CRS-207 will be administered on Day 1 once every 6 weeks (every other cycle).
- Phase 1: CRS-207/IDO 100 mg (Type: EXPERIMENTAL): CRS-207 administered in 3-week cycles, IDO administered twice daily (BID).~* CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~* IDO (100 milligrams \[mg\]) administered by mouth (PO) BID, starting on Day 2 of the first CRS-207 treatment cycle.
- Phase 1: CRS-207/IDO 300 mg (Type: EXPERIMENTAL): CRS-207 administered in 3-week cycles, IDO administered BID.~* CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~* IDO (300 mg) administered PO BID, starting on Day 2 of the first CRS-207 treatment cycle.
- Phase 2: CRS-207/Pembro/IDO (Type: EXPERIMENTAL): CRS-207 and pembrolizumab (pembro) administered in 3-week cycles, IDO administered BID.~* CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~* Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles.~* IDO (300 mg) administered PO BID, starting on Day 3 of the first CRS-207 treatment cycle.
- Phase 2: CRS-207/Pembro (Type: EXPERIMENTAL): CRS-207 and pembro administered in 3-week cycles.~* CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~* Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues